Sex and genetic determinants of direct-acting oral anticoagulant (DOAC) efficacy and adverse outcomes

直接作用口服抗凝剂（DOAC）疗效和不良后果的性别和遗传决定因素

• 批准号: 365152
• 负责人: Schwarz Ute I
• 金额: $ 14.51万
• 依托单位: University of Western Ontario
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2017
• 资助国家: 加拿大
• 起止时间: 2017-06-01 至 2019-06-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=365152&lang=en
• 关键词: Oral Anticoagulation; Sex-Drug-Gene Interaction

Direct-acting oral anticoagulants (DOACs) are a new type of blood thinners widely used to prevent stroke in patients with atrial fibrillation (AF), a disorder associated with irregular heartbeat, or venous thromboembolism (VTE), a harmful blood clot in a

直接作用口服抗凝剂（DOACs）是一种新型的血液稀释剂，广泛用于房颤（AF）患者的中风预防，房颤（AF）是一种与心律不齐或静脉血栓栓塞（VTE）相关的疾病